Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Dengue vascular leak syndrome: insights into potentially new treatment modalities.

Durbin AP.

J Clin Invest. 2019 Oct 1;129(10):4072-4073. doi: 10.1172/JCI131170.

2.

Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response.

Krubiner CB, Faden RR, Karron RA, Little MO, Lyerly AD, Abramson JS, Beigi RH, Cravioto AR, Durbin AP, Gellin BG, Gupta SB, Kaslow DC, Kochhar S, Luna F, Saenz C, Sheffield JS, Tindana PO; PREVENT Working Group.

Vaccine. 2019 May 3. pii: S0264-410X(19)30045-3. doi: 10.1016/j.vaccine.2019.01.011. [Epub ahead of print] Review.

3.

Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.

Swanstrom JA, Nivarthi UK, Patel B, Delacruz MJ, Yount B, Widman DG, Durbin AP, Whitehead SS, De Silva AM, Baric RS.

J Infect Dis. 2019 Jun 19;220(2):219-227. doi: 10.1093/infdis/jiz109.

4.

Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model.

Nivarthi UK, Tu HA, Delacruz MJ, Swanstrom J, Patel B, Durbin AP, Whitehead SS, Pierce KK, Kirkpatrick BD, Baric RS, Nguyen N, Emerling DE, de Silva AM, Diehl SA.

EBioMedicine. 2019 Mar;41:465-478. doi: 10.1016/j.ebiom.2019.02.060. Epub 2019 Mar 8.

5.

What is the prospect of a safe and effective dengue vaccine for travellers?

Durbin AP, Gubler DJ.

J Travel Med. 2019 Sep 2;26(6). pii: tay153. doi: 10.1093/jtm/tay153. No abstract available.

PMID:
30657935
6.

Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization.

Gallichotte EN, Baric TJ, Nivarthi U, Delacruz MJ, Graham R, Widman DG, Yount BL, Durbin AP, Whitehead SS, de Silva AM, Baric RS.

Cell Rep. 2018 Oct 30;25(5):1214-1224. doi: 10.1016/j.celrep.2018.10.006.

7.

Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus.

Katzelnick LC, Coello Escoto A, McElvany BD, Chávez C, Salje H, Luo W, Rodriguez-Barraquer I, Jarman R, Durbin AP, Diehl SA, Smith DJ, Whitehead SS, Cummings DAT.

PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006862. doi: 10.1371/journal.pntd.0006862. eCollection 2018 Oct.

8.

Impact of Dengue Virus Serotype 2 Strain Diversity on Serological Immune Responses to Dengue.

Keasey SL, Smith JL, Fernandez S, Durbin AP, Zhao BM, Ulrich RG.

ACS Infect Dis. 2018 Dec 14;4(12):1705-1717. doi: 10.1021/acsinfecdis.8b00185. Epub 2018 Nov 5.

PMID:
30347144
9.

Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers.

Popper SJ, Strouts FR, Lindow JC, Cheng HK, Montoya M, Balmaseda A, Durbin AP, Whitehead SS, Harris E, Kirkpatrick BD, Relman DA.

J Infect Dis. 2018 Nov 5;218(12):1911-1921. doi: 10.1093/infdis/jiy434.

10.

Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.

Vannice KS, Wilder-Smith A, Barrett ADT, Carrijo K, Cavaleri M, de Silva A, Durbin AP, Endy T, Harris E, Innis BL, Katzelnick LC, Smith PG, Sun W, Thomas SJ, Hombach J.

Vaccine. 2018 Jun 7;36(24):3411-3417. doi: 10.1016/j.vaccine.2018.02.062. Epub 2018 Mar 7.

11.

Zika Vaccines: Role for Controlled Human Infection.

Durbin AP, Whitehead SS.

J Infect Dis. 2017 Dec 16;216(suppl_10):S971-S975. doi: 10.1093/infdis/jix491. Review.

12.

Global Assessment of Dengue Virus-Specific CD4+ T Cell Responses in Dengue-Endemic Areas.

Grifoni A, Angelo MA, Lopez B, O'Rourke PH, Sidney J, Cerpas C, Balmaseda A, Silveira CGT, Maestri A, Costa PR, Durbin AP, Diehl SA, Phillips E, Mallal S, De Silva AD, Nchinda G, Nkenfou C, Collins MH, de Silva AM, Lim MQ, Macary PA, Tatullo F, Solomon T, Satchidanandam V, Desai A, Ravi V, Coloma J, Turtle L, Rivino L, Kallas EG, Peters B, Harris E, Sette A, Weiskopf D.

Front Immunol. 2017 Oct 13;8:1309. doi: 10.3389/fimmu.2017.01309. eCollection 2017.

13.

Rapid changes in serum cytokines and chemokines in response to inactivated influenza vaccination.

Talaat KR, Halsey NA, Cox AB, Coles CL, Durbin AP, Ramakrishnan A, Bream JH.

Influenza Other Respir Viruses. 2018 Mar;12(2):202-210. doi: 10.1111/irv.12509. Epub 2018 Jan 4.

14.

Dengue vaccines: implications for dengue control.

Robinson ML, Durbin AP.

Curr Opin Infect Dis. 2017 Oct;30(5):449-454. doi: 10.1097/QCO.0000000000000394. Review.

PMID:
28719400
15.

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.

Whitehead SS, Durbin AP, Pierce KK, Elwood D, McElvany BD, Fraser EA, Carmolli MP, Tibery CM, Hynes NA, Jo M, Lovchik JM, Larsson CJ, Doty EA, Dickson DM, Luke CJ, Subbarao K, Diehl SA, Kirkpatrick BD.

PLoS Negl Trop Dis. 2017 May 8;11(5):e0005584. doi: 10.1371/journal.pntd.0005584. eCollection 2017 May.

16.

Antibody Responses to Zika Virus Infections in Environments of Flavivirus Endemicity.

Keasey SL, Pugh CL, Jensen SMR, Smith JL, Hontz RD, Durbin AP, Dudley DM, O'Connor DH, Ulrich RG.

Clin Vaccine Immunol. 2017 Apr 5;24(4). pii: e00036-17. doi: 10.1128/CVI.00036-17. Print 2017 Apr.

17.

Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.

Grifoni A, Angelo M, Sidney J, Paul S, Peters B, de Silva AD, Phillips E, Mallal S, Diehl SA, Botten J, Boyson J, Kirkpatrick BD, Whitehead SS, Durbin AP, Sette A, Weiskopf D.

J Virol. 2017 Mar 29;91(8). pii: e02133-16. doi: 10.1128/JVI.02133-16. Print 2017 Apr 15.

18.

A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers.

Pierce KK, Whitehead SS, Kirkpatrick BD, Grier PL, Jarvis A, Kenney H, Carmolli MP, Reynolds C, Tibery CM, Lovchik J, Janiak A, Luke CJ, Durbin AP, Pletnev AG.

J Infect Dis. 2017 Jan 1;215(1):52-55. doi: 10.1093/infdis/jiw501. Epub 2016 Oct 25.

19.

Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.

Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE Jr, de Silva AM.

J Virol. 2017 Feb 14;91(5). pii: e02041-16. doi: 10.1128/JVI.02041-16. Print 2017 Mar 1.

20.

Human CD4+ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity.

Angelo MA, Grifoni A, O'Rourke PH, Sidney J, Paul S, Peters B, de Silva AD, Phillips E, Mallal S, Diehl SA, Kirkpatrick BD, Whitehead SS, Durbin AP, Sette A, Weiskopf D.

J Virol. 2017 Feb 14;91(5). pii: e02147-16. doi: 10.1128/JVI.02147-16. Print 2017 Mar 1.

21.

Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency.

Vannice KS, Giersing BK, Kaslow DC, Griffiths E, Meyer H, Barrett A, Durbin AP, Wood D, Hombach J.

Vaccine. 2016 Dec 20. pii: S0264-410X(16)30969-0. doi: 10.1016/j.vaccine.2016.10.034. [Epub ahead of print]

PMID:
27916410
22.

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.

Talaat KR, Ellis RD, Hurd J, Hentrich A, Gabriel E, Hynes NA, Rausch KM, Zhu D, Muratova O, Herrera R, Anderson C, Jones D, Aebig J, Brockley S, MacDonald NJ, Wang X, Fay MP, Healy SA, Durbin AP, Narum DL, Wu Y, Duffy PE.

PLoS One. 2016 Oct 17;11(10):e0163144. doi: 10.1371/journal.pone.0163144. eCollection 2016.

23.

Vaccine Development for Zika Virus-Timelines and Strategies.

Durbin AP.

Semin Reprod Med. 2016 Sep;34(5):299-304. Epub 2016 Sep 8. Review.

PMID:
27607566
24.

Dengue Antibody and Zika: Friend or Foe?

Durbin AP.

Trends Immunol. 2016 Oct;37(10):635-636. doi: 10.1016/j.it.2016.08.006. Epub 2016 Sep 3.

PMID:
27599407
25.

A Dengue Vaccine.

Durbin AP.

Cell. 2016 Jun 30;166(1):1. doi: 10.1016/j.cell.2016.06.036.

26.

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.

Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, Carmolli MP, Luke CJ, Diehl SA, Durbin AP.

Sci Transl Med. 2016 Mar 16;8(330):330ra36. doi: 10.1126/scitranslmed.aaf1517. Epub 2016 Mar 16.

PMID:
27089205
27.

A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.

Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Opert K, Jarvis AP, Sabundayo BP, McElvany BD, Sendra EA, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS.

J Infect Dis. 2016 Sep 15;214(6):832-5. doi: 10.1093/infdis/jiw067. Epub 2016 Feb 16.

28.

Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali.

Vannice KS, Keita M, Sow SO, Durbin AP, Omer SB, Moulton LH, Yaméogo TM, Zuber PL, Onwuchekwa U, Sacko M, Diomandé FV, Halsey NA.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S493-500. doi: 10.1093/cid/civ497.

29.

WITHDRAWN: Dengue Human Infection Models to Advance Dengue Vaccine Development.

Larsen CP, Whitehead SS, Durbin AP.

Vaccine. 2015 Oct 27. pii: S0264-410X(15)01424-3. doi: 10.1016/j.vaccine.2015.09.113. [Epub ahead of print]

PMID:
26501186
30.

Dengue human infection models to advance dengue vaccine development.

Larsen CP, Whitehead SS, Durbin AP.

Vaccine. 2015 Dec 10;33(50):7075-82. doi: 10.1016/j.vaccine.2015.09.052. Epub 2015 Sep 28.

31.

The dengue vaccine pipeline: Implications for the future of dengue control.

Schwartz LM, Halloran ME, Durbin AP, Longini IM Jr.

Vaccine. 2015 Jun 26;33(29):3293-8. doi: 10.1016/j.vaccine.2015.05.010. Epub 2015 May 16. Review.

32.

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.

Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS.

J Infect Dis. 2015 Sep 1;212(5):702-10. doi: 10.1093/infdis/jiv082. Epub 2015 Mar 22.

33.

Mechanism and significance of cell type-dependent neutralization of flaviviruses.

Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, Whitehead SS, Pierson TC.

J Virol. 2014 Jul;88(13):7210-20. doi: 10.1128/JVI.03690-13. Epub 2014 Apr 16.

34.

Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis.

Althouse BM, Durbin AP, Hanley KA, Halstead SB, Weaver SC, Cummings DA.

Virology. 2014 Mar;452-453:237-46. doi: 10.1016/j.virol.2014.01.015. Epub 2014 Feb 14. Review.

35.

The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.

VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2013;9(12):e1003761. doi: 10.1371/journal.ppat.1003761. Epub 2013 Dec 5.

36.

The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.

Durbin AP, Wright PF, Cox A, Kagucia W, Elwood D, Henderson S, Wanionek K, Speicher J, Whitehead SS, Pletnev AG.

Vaccine. 2013 Nov 19;31(48):5772-7. doi: 10.1016/j.vaccine.2013.07.064. Epub 2013 Aug 19.

37.

Response to Ruiz-Alejo et al.

Durbin AP, Whitehead SS.

J Infect Dis. 2013 Oct 1;208(7):1184. doi: 10.1093/infdis/jit298. Epub 2013 Jul 11. No abstract available.

PMID:
23852125
38.

Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.

Lindow JC, Durbin AP, Whitehead SS, Pierce KK, Carmolli MP, Kirkpatrick BD.

Vaccine. 2013 Jul 18;31(33):3347-52. doi: 10.1016/j.vaccine.2013.05.075. Epub 2013 Jun 2.

39.

Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.

Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE Jr.

J Infect Dis. 2013 Jun 15;207(12):1898-908. doi: 10.1093/infdis/jit119. Epub 2013 Mar 22.

40.

Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.

Durbin AP, Mayer SV, Rossi SL, Amaya-Larios IY, Ramos-Castaneda J, Eong Ooi E, Jane Cardosa M, Munoz-Jordan JL, Tesh RB, Messer WB, Weaver SC, Vasilakis N.

Virology. 2013 Apr 25;439(1):34-41. doi: 10.1016/j.virol.2013.01.018. Epub 2013 Feb 26.

41.

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS.

J Infect Dis. 2013 Mar 15;207(6):957-65. doi: 10.1093/infdis/jis936. Epub 2013 Jan 17.

42.

The dengue human challenge model: has the time come to accept this challenge?

Durbin AP, Whitehead SS.

J Infect Dis. 2013 Mar 1;207(5):697-9. doi: 10.1093/infdis/jis749. Epub 2012 Dec 5. No abstract available.

PMID:
23225898
43.

Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.

Ellis RD, Wu Y, Martin LB, Shaffer D, Miura K, Aebig J, Orcutt A, Rausch K, Zhu D, Mogensen A, Fay MP, Narum DL, Long C, Miller L, Durbin AP.

PLoS One. 2012;7(10):e46094. doi: 10.1371/journal.pone.0046094. Epub 2012 Oct 4.

44.

Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans.

Lindow JC, Borochoff-Porte N, Durbin AP, Whitehead SS, Fimlaid KA, Bunn JY, Kirkpatrick BD.

PLoS Negl Trop Dis. 2012;6(7):e1742. doi: 10.1371/journal.pntd.0001742. Epub 2012 Jul 17.

45.

Next-generation dengue vaccines: novel strategies currently under development.

Durbin AP, Whitehead SS.

Viruses. 2011 Oct;3(10):1800-14. doi: 10.3390/v3101800. Epub 2011 Sep 26.

46.

A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.

Durbin AP, Whitehead SS, Shaffer D, Elwood D, Wanionek K, Thumar B, Blaney JE, Murphy BR, Schmidt AC.

PLoS Negl Trop Dis. 2011 Aug;5(8):e1267. doi: 10.1371/journal.pntd.0001267. Epub 2011 Aug 2.

47.

Decay and persistence of maternal dengue antibodies among infants in Bangkok.

van Panhuis WG, Luxemburger C, Pengsaa K, Limkittikul K, Sabchareon A, Lang J, Durbin AP, Cummings DA.

Am J Trop Med Hyg. 2011 Aug;85(2):355-62. doi: 10.4269/ajtmh.2011.11-0125.

48.

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.

Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS.

Vaccine. 2011 Sep 23;29(42):7242-50. doi: 10.1016/j.vaccine.2011.07.023. Epub 2011 Jul 21. Review.

49.

A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus.

Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2011 Jun;7(6):e1002111. doi: 10.1371/journal.ppat.1002111. Epub 2011 Jun 30.

50.

Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.

Durbin AP, Schmidt A, Elwood D, Wanionek KA, Lovchik J, Thumar B, Murphy BR, Whitehead SS.

J Infect Dis. 2011 Feb 1;203(3):327-34. doi: 10.1093/infdis/jiq059. Epub 2010 Dec 14.

Supplemental Content

Loading ...
Support Center